These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 21592479

  • 1. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis.
    Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B.
    Atherosclerosis; 2011 Aug; 217(2):492-8. PubMed ID: 21592479
    [Abstract] [Full Text] [Related]

  • 2. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
    Tenenbaum A, Fisman EZ.
    Cardiovasc Diabetol; 2012 Oct 11; 11():125. PubMed ID: 23057687
    [Abstract] [Full Text] [Related]

  • 3. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
    Tenenbaum A, Fisman EZ.
    Cardiovasc Diabetol; 2010 Jun 15; 9():24. PubMed ID: 20550659
    [Abstract] [Full Text] [Related]

  • 4. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis.
    Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P.
    J Cardiovasc Pharmacol; 2011 Feb 15; 57(2):267-72. PubMed ID: 21052016
    [Abstract] [Full Text] [Related]

  • 5. The effect of fibrates on lowering low-density lipoprotein cholesterol and cardiovascular risk reduction: a systemic review and meta-analysis.
    Kim KA, Kim NJ, Choo EH.
    Eur J Prev Cardiol; 2024 Feb 15; 31(3):291-301. PubMed ID: 37855457
    [Abstract] [Full Text] [Related]

  • 6. Fibrates in the management of atherogenic dyslipidemia.
    Okopień B, Buldak L, Bołdys A.
    Expert Rev Cardiovasc Ther; 2017 Dec 15; 15(12):913-921. PubMed ID: 29183206
    [Abstract] [Full Text] [Related]

  • 7. Do persons with diabetes benefit from combination statin and fibrate therapy?
    Rosenblit PD.
    Curr Cardiol Rep; 2012 Feb 15; 14(1):112-24. PubMed ID: 22213157
    [Abstract] [Full Text] [Related]

  • 8. Fibrate therapy and flow-mediated dilation: A systematic review and meta-analysis of randomized placebo-controlled trials.
    Sahebkar A, Giua R, Pedone C, Ray KK, Vallejo-Vaz AJ, Costanzo L.
    Pharmacol Res; 2016 Sep 15; 111():163-179. PubMed ID: 27320045
    [Abstract] [Full Text] [Related]

  • 9. The role of fibrate treatment in dyslipidemia: an overview.
    Katsiki N, Nikolic D, Montalto G, Banach M, Mikhailidis DP, Rizzo M.
    Curr Pharm Des; 2013 Sep 15; 19(17):3124-31. PubMed ID: 23317397
    [Abstract] [Full Text] [Related]

  • 10. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
    Halcox JP, Banegas JR, Roy C, Dallongeville J, De Backer G, Guallar E, Perk J, Hajage D, Henriksson KM, Borghi C.
    BMC Cardiovasc Disord; 2017 Jun 17; 17(1):160. PubMed ID: 28623902
    [Abstract] [Full Text] [Related]

  • 11. Benefits and risks of the treatment with fibrates--a comprehensive summary.
    Okopień B, Bułdak Ł, Bołdys A.
    Expert Rev Clin Pharmacol; 2018 Nov 17; 11(11):1099-1112. PubMed ID: 30328735
    [Abstract] [Full Text] [Related]

  • 12. Impact of fibrate therapy on plasma plasminogen activator inhibitor-1: a systematic review and meta-analysis of randomized controlled trials.
    Sahebkar A, Simental-Mendía LE, Watts GF, Golledge J.
    Atherosclerosis; 2015 May 17; 240(1):284-96. PubMed ID: 25828270
    [Abstract] [Full Text] [Related]

  • 13. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
    Brea Hernando ÁJ.
    Clin Investig Arterioscler; 2014 Jul 17; 26 Suppl 1():3-6. PubMed ID: 25043539
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis.
    Riaz H, Khan SU, Rahman H, Shah NP, Kaluski E, Lincoff AM, Nissen SE.
    Eur J Prev Cardiol; 2019 Mar 17; 26(5):533-543. PubMed ID: 30861690
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: a meta-analysis.
    Choi HD, Shin WG, Lee JY, Kang BC.
    Vascul Pharmacol; 2015 Mar 17; 65-66():23-30. PubMed ID: 25451563
    [Abstract] [Full Text] [Related]

  • 17. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
    Brea A, Millán J, Ascaso JF, Blasco M, Díaz A, González-Santos P, Hernández-Mijares A, Mantilla T, Pedro-Botet JC, Pintó X, en nombre del Foro de la Dislipemia Aterogénica.
    Clin Investig Arterioscler; 2016 Mar 17; 28(6):295-301. PubMed ID: 27609708
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Optimal pharmacotherapy to combat the atherogenic lipid triad.
    Chapman MJ, Redfern JS, McGovern ME, Giral P.
    Curr Opin Cardiol; 2011 Sep 17; 26(5):403-11. PubMed ID: 21730827
    [Abstract] [Full Text] [Related]

  • 20. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
    Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A, Watts GF, European Atherosclerosis Society Consensus Panel.
    Eur Heart J; 2011 Jun 17; 32(11):1345-61. PubMed ID: 21531743
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.